Home   >  
Angiogenesis/Protein Tyrosine Kinase
  >  
Src/Bcr Abl

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

Src/Bcr Abl

Chemical Structure Cat. No. Product Name CAS No.
1 NM-PP1 Chemical Structure
 BCP09491 1 NM-PP1 221244-14-0
1 NM-PP1 is a cell-permeable PP1 analog that acts as a potent and selective inhibitor of mutant kinases over their wild-type progenitors.
TX-1918 Chemical Structure
 BCP16358 TX-1918 503473-32-3
TX-1918 is a cell-permeable tyrphostin derivative that inhibits eukaryotic elongation factor-2 kinase (eEF-2K; IC50 = 440 nM).
AP-23464 Chemical Structure
 BCP22041 AP-23464 845895-51-4
AP23464 is a potent adenosine 5'-triphosphate (ATP)-based inhibitor of Src and Abl kinases, displays antiproliferative activity against a human CML cell line and Bcr-Abl-transduced Ba/F3 cells (IC(50) = 14 nM. AP23464 ablates Bcr-Abl tyrosine phosphorylation, blocks cell cycle progression, and promotes apoptosis of Bcr-Abl-expressing cells.
AP23848 Chemical Structure
 BCP21601 AP23848 834894-21-2
AP23848 is a potent Bcr-Abl inhibitor.
AST-487 Chemical Structure
 BCP21589 AST-487 630124-46-8
AST 487 is a RET kinase inhibitor with IC50 of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC50 of 520 nM.
BGG463 Chemical Structure
 BCP25389 BGG463 890129-26-7
BGG463 can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of 0.25 μM, 0.09 μM and 0.590 μM, respectively.
Radotinib Dihydrochloride Chemical Structure
 BCP28917 Radotinib Dihydrochloride 926037-85-6
Radotinib, also known as IY-5511, is an orally available, a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity.
Nilotinib hydrochloride Chemical Structure
 BCP29532 Nilotinib hydrochloride 923288-95-3
Nilotinib, also known as AMN-107, is an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activit
BCR-ABL-IN-2 Chemical Structure
 BCP29509 BCR-ABL-IN-2 897369-18-5
BCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC50s of 57 nM, 773 nm for ABL1native and ABL1T315I, respectively.
AT9283 Chemical Structure
 BCP11714 AT9283 896466-04-9
AT9283 is a multi-targeted inhibitor with IC50s of 1.2 nM, 1.1 nM for JAK2 and JAK3, respectively, and is also potent to Aurora A, Aurora B and Abl(T315I).
123下一页末页共 70 条记录 1 / 7 页 
0086-13720134139